Experts Discuss CELMoD Agents for Treating Multiple Myeloma
Listen to Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Niels van de Donk, MD, PhD, address key questions on CELMoD agent therapy for multiple myeloma, including combination strategies, adverse event management, and where CELMoD agents may best fit within current and future treatment strategies.
Decera Clinical Education Oncology Podcast · Niels van de Donk MD PhD, Jesus Berdeja MD, Amrita Krishnan MD FACP
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this podcast episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Niels van de Donk, MD, PhD, address key questions on CELMoD agent therapy for multiple myeloma, including:
- Combination strategies
- Adverse event management
- Where CELMoD agents may best fit within current and future treatment strategies
Presenters:
Jesus Berdeja, MD
Director of Multiple Myeloma Research
Greco-Hainsworth Centers for Research
Tennessee Oncology
Nashville, Tennessee
Amrita Krishnan, MD, FACP
Director, Judy and Bernard Center for Myeloma, City of Hope
Nason Hollingsworth Family Chair Myeloma
Executive Director, Hematology, City of Hope Orange County
Professor Hematology/HCT
Irvine, California
Niels van de Donk, MD, PhD
Professor of Hematology
Department of Hematology
Amsterdam UMC, Location VUmc
Amsterdam, Netherlands
Content based on an online CME program supported by an educational grant from Bristol Myers Squibb.
Link to full program:
https://bit.ly/4qvRwQM
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.